Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance
HALOUpdates Preliminary Unaudited 2025 Estimates: - Total Revenue of $1,385 - $1,400 million, YoY Growth of 36% to 38%1 - Royalty Revenue of $865 - $870 million, YoY Growth of 51% to 52%1 Raises 2026 Financial Guidance Ranges: - Increases Total Revenue to $1,710 - $1,810 million, YoY Growth...
Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update
HALOSAN DIEGO, Jan. 20, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will host an Investor Conference Call on Wednesday, January 28, 2026, at 5:30 am PT / 8:30 am ET. On the call, Dr. Helen Torley, President and Chief Executive Officer, and...
Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany
HALOSAN DIEGO, Dec. 4, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme), announced today that a German court has granted its request for a preliminary injunction ordering Merck to refrain from distributing and offering Keytruda SC in Germany. The Munich Regional...
Halozyme to Participate at Upcoming Investor Conferences
HALOSAN DIEGO, Aug. 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, and Tram Bui, VP of Investor Relations and Corporate Communications, are scheduled to participate and host...
Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 5 Years
HALOHC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $72 Price Target
HALOWhat's Driving the Market Sentiment Around Halozyme Therapeutics?
HALOPrice Over Earnings Overview: Halozyme Therapeutics
HALOHalozyme Says Bristol Myers Squibb Secures EC Approval For Opdivo Subcutaneous Formulation Developed With ENHANZE
HALOMorgan Stanley Downgrades Halozyme Therapeutics to Equal-Weight, Lowers Price Target to $62
HALOLeerink Partners Downgrades Halozyme Therapeutics to Underperform, Announces $47 Price Target
HALOHere's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 15 Years
HALOWells Fargo Maintains Equal-Weight on Halozyme Therapeutics, Raises Price Target to $65
HALOHalozyme Therapeutics Raises FY2025 Adj EPS Guidance from $4.95-$5.35 to $5.30-$5.70 vs $5.00 Est; Raises FY2025 Sales Guidance from $1.15B-$1.23B to $1.20B-$1.28B vs $1.20B Est
HALOHalozyme Therapeutics Q1 Adj. EPS $1.11 Beats $0.94 Estimate, Sales $264.86M Beat $230.18M Estimate
HALOInsights into Halozyme Therapeutics's Upcoming Earnings
HALOHalozyme Announces argenx Received A Positive CHMP Opinion Recommending EC Approval Of VYVGART 1000mg Developed With VYVGART 1000mg For Chronic Inflammatory Demyelinating Polyneuropathy
HALODeep Dive Into Halozyme Therapeutics Stock: Analyst Perspectives (5 Ratings)
HALOHC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $72 Price Target
HALOHere's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 5 Years
HALOJP Morgan Maintains Neutral on Halozyme Therapeutics, Raises Price Target to $58
HALOPeering Into Halozyme Therapeutics's Recent Short Interest
HALOHalozyme Therapeutics Announces European Commission Approved Subcutaneous DARZALEX-Based Quadruplet Regimen For Treatment Of Patients With Newly Diagnosed Multiple Myeloma, Regardless Of Transplant Eligibility
HALOHalozyme Therapeutics Announced That Janssen-Cilag International NV, A J&J Company, Has Received European Commission Marketing Authorization Of The Subcutaneous Formulation Of RYBREVANT, In Combination With LAZCLUZE, For The First-Line Treatment Of Adult
HALOHC Wainwright & Co. Reiterates Buy on Halozyme Therapeuticsto Buy
HALOAssessing Halozyme Therapeutics: Insights From 9 Financial Analysts
HALOBenchmark Reiterates Buy on Halozyme Therapeutics, Maintains $75 Price Target
HALOHC Wainwright & Co. Maintains Buy on Halozyme Therapeutics, Raises Price Target to $72
HALOHalozyme Therapeutics Q4 2024 Adj EPS $1.26 Beats $1.16 Estimate, Sales $298.00M Beat $288.24M Estimate
HALOAnalyst Expectations For Halozyme Therapeutics's Future
HALOWells Fargo Maintains Equal-Weight on Halozyme Therapeutics, Lowers Price Target to $57
HALOPiper Sandler Maintains Neutral on Halozyme Therapeutics, Raises Price Target to $53
HALOHC Wainwright & Co. Maintains Buy on Halozyme Therapeutics, Raises Price Target to $70
HALOBreaking Down Halozyme Therapeutics: 10 Analysts Share Their Views
HALOHC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $68 Price Target
HALOLooking Into Halozyme Therapeutics's Recent Short Interest
HALOPiper Sandler Maintains Neutral on Halozyme Therapeutics, Raises Price Target to $52
HALOJMP Securities Maintains Market Outperform on Halozyme Therapeutics, Raises Price Target to $73
HALOHC Wainwright & Co. Maintains Buy on Halozyme Therapeutics, Raises Price Target to $68
HALOHalozyme Therapeutics Sees FY24 Adj. EPS $4.00-$4.20 To $3.96 Est.; Revenue $970M-$1.020B Vs $983.852M Est.
HALOHalozyme Therapeutics Q3 2024 Adj. EPS $1.27 Beats $0.98 Estimate, Sales $290.084M Beat $251.059M Estimate
HALOHC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $50 Price Target
HALOHalozyme Discloses That Bristol Myers Squibb Received Updated Action Date From U.S. FDA For Subcutaneous Nivolumab Co-Formulated with ENHANZE (Halozyme's Proprietary Recombinant Human Hyaluronidase Enzyme); The Updated Goal Date Is December 29, 2024
HALOMorgan Stanley Initiates Coverage On Halozyme Therapeutics with Overweight Rating, Announces Price Target of $50
HALO